Governments across the globe are rushing to access fragmented vaccine production after manufacturing setbacks deprived European Union members of drugs made on their own soil this year.
For Allison Martell's latest contributions to The Japan Times, see below:
High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their effectiveness, some experts say. CanSino Biologics' vaccine, approved for military use in China, is a ...
As infection rates spike nationwide, many labs aren't running anywhere near capacity because of supply-chain bottlenecks.